John Creemers
Katholieke Universiteit Leuven
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by John Creemers.
Nature Medicine | 2005
Donalyn Scheuner; Dirk Vander Mierde; Benbo B. Song; Daisy Flamez; John Creemers; Katsura Tsukamoto; Mark Ribick; Frans Schuit; Randal J. Kaufman
Type 2 diabetes is a disorder of hyperglycemia resulting from failure of beta cells to produce adequate insulin to accommodate an increased metabolic demand. Here we show that regulation of mRNA translation through phosphorylation of eukaryotic initiation factor 2 (eIF2α) is essential to preserve the integrity of the endoplasmic reticulum (ER) and to increase insulin production to meet the demand imposed by a high-fat diet. Accumulation of unfolded proteins in the ER activates phosphorylation of eIF2α at Ser51 and inhibits translation. To elucidate the role of this pathway in beta-cell function we studied glucose homeostasis in Eif2s1 tm1Rjk mutant mice, which have an alanine substitution at Ser51. Heterozygous (Eif2s1 +/tm1Rjk) mice became obese and diabetic on a high-fat diet. Profound glucose intolerance resulted from reduced insulin secretion accompanied by abnormal distension of the ER lumen, defective trafficking of proinsulin, and a reduced number of insulin granules in beta cells. We propose that translational control couples insulin synthesis with folding capacity to maintain ER integrity and that this signal is essential to prevent diet-induced type 2 diabetes.
Journal of Clinical Investigation | 2003
Robert S. Jackson; John Creemers; I. Sadaf Farooqi; Marie-Laure Raffin-Sanson; Andrea Varro; Graham J. Dockray; Jens J. Holst; Patricia L. Brubaker; Pierre Corvol; Kenneth S. Polonsky; Diane Ostrega; Kenneth L. Becker; Xavier Bertagna; John C. Hutton; Anne White; Mehul T. Dattani; Khalid Hussain; Stephen J. Middleton; Thomasina M. Nicole; Peter J. Milla; Keith J. Lindley; Stephen O’Rahilly
We have previously described the only reported case of human proprotein convertase 1 (PC1) deficiency, in a female (Subject A) with obesity, hypogonadism, hypoadrenalism, and reactive hypoglycemia. We now report the second case of human PC1 deficiency (Subject B), also due to compound heterozygosity for novel missense and nonsense mutations. While both subjects shared the phenotypes of obesity, hypoadrenalism, reactive hypoglycemia, and elevated circulating levels of certain prohormones, the clinical presentation of Subject B was dominated by severe refractory neonatal diarrhea, malabsorptive in type. Subsequent investigation of Subject A revealed marked small-intestinal absorptive dysfunction, which was not previously clinically suspected. We postulate that PC1, presumably in the enteroendocrine cells, is essential for the normal absorptive function of the human small intestine. The differences in the nature and severity of presentation between the two cases cannot readily be explained on the basis of allelic heterogeneity, as the nonsense and missense mutations from both subjects had comparably severe effects on the catalytic activity of PC1. Despite Subject As negligible PC1 activity, some mature ACTH and glucagon-like peptide 17-36(amide) were detectable in her plasma, suggesting that the production of these hormones, at least in humans, does not have an absolute dependence on PC1. The presence of severe obesity and the absence of growth retardation in both subjects contrast markedly with the phenotype of mice lacking PC1 and suggest that the precise physiological repertoire of this enzyme may vary between mammalian species.
Nature Genetics | 2008
Michael Benzinou; John Creemers; Hélène Choquet; Stéphane Lobbens; Christian Dina; Emmanuelle Durand; Audrey Guérardel; Philippe Boutin; Béatrice Jouret; Barbara Heude; Beverley Balkau; Jean Tichet; Michel Marre; Natascha Potoczna; Fritz Horber; Catherine Le Stunff; Sébastien Czernichow; Annelli Sandbæk; Torsten Lauritzen; Knut Borch-Johnsen; Gitte Andersen; Wieland Kiess; Antje Körner; Peter Kovacs; Peter Jacobson; Lena M.S. Carlsson; Andrew Walley; Torben Jørgensen; Torben Hansen; Oluf Pedersen
Mutations in PCSK1 cause monogenic obesity. To assess the contribution of PCSK1 to polygenic obesity risk, we genotyped tag SNPs in a total of 13,659 individuals of European ancestry from eight independent case-control or family-based cohorts. The nonsynonymous variants rs6232, encoding N221D, and rs6234-rs6235, encoding the Q665E-S690T pair, were consistently associated with obesity in adults and children (P = 7.27 × 10−8 and P = 2.31 × 10−12, respectively). Functional analysis showed a significant impairment of the N221D-mutant PC1/3 protein catalytic activity.
The FASEB Journal | 2003
Neil A. Taylor; Wim J.M. Van de Ven; John Creemers
The proprotein convertases (PCs) are a seven‐member family of endoproteases that activate proproteins by cleavage at basic motifs. Expression patterns for individual PCs vary widely, and all cells express several members. The list of substrates activated by PCs has grown to include neuropeptides, peptide hormones, growth and differentiation factors, receptors, enzymes, adhesion molecules, blood coagulation factors, plasma proteins, viral coat proteins, and bacterial toxins. It has become clear that the PC family plays a crucial role in a variety of physiological processes and is involved in the pathology of diseases such as cancer, viral infection, and Alzheimers disease. Recent studies using PC inhibitors have demonstrated their potential as therapeutic targets. Despite the avalanche of in vitro data, the physiological role of individual PCs has remained largely elusive. Recently, however, knockout mouse models have been developed for furin, PC1, PC2, PC4, PC6B, LPC, and PACE4, and human patients with PC1 deficiency have been identified. The phenotypes range from undetectable to early embryonic lethality. The major lesson learned from these studies is that specific PC‐substrate pairs do exist, but that there is substantial redundancy for the majority of substrates. To some extent, redundancy may be cell type and even species dependent.
Journal of Cell Biology | 2003
Bart De Cat; S Muyldermans; Christien Coomans; Gisèle Degeest; Bernadette Vanderschueren; John Creemers; Frédéric Biemar; Bernard Peers; Guido David
Glypican (GPC)-3 inhibits cell proliferation and regulates cell survival during development. This action is demonstrated by GPC3 loss-of-function mutations in humans and mice. Here, we show that the GPC3 core protein is processed by a furinlike convertase. This processing is essential for GPC3 modulating Wnt signaling and cell survival in vitro and for supporting embryonic cell movements in zebrafish. The processed GPC3 core protein is necessary and sufficient for the cell-specific induction of apoptosis, but in vitro effects on canonical and noncanonical Wnt signaling additionally require substitution of the core protein with heparan sulfate. Wnt 5A physically associates only with processed GPC3, and only a form of GPC3 that can be processed by a convertase is able to rescue epiboly and convergence/extension movements in GPC3 morphant embryos. Our data imply that the Simpson–Golabi–Behmel syndrome may in part result from a loss of GPC3 controls on Wnt signaling, and suggest that this function requires the cooperation of both the protein and the heparan sulfate moieties of the proteoglycan.
Journal of Neurochemistry | 2001
Elvira Lopez-Perez; Yue Zhang; Stuart J. Frank; John Creemers; Nabil G. Seidah; Frédéric Checler
The β‐amyloid precursor protein (βAPP) undergoes a physiological cleavage triggered by one or several proteolytic activities referred to as α‐secretases, leading to the secretion of sAPPα. Several lines of evidence indicate that the α‐secretase cleavage is a highly regulated process. Thus, besides constitutive production of sAPPα, several studies have reported on protein kinase C‐regulated sAPPα secretion. Studies aimed at identifying α‐secretase(s) candidates suggest the involvement of enzymes belonging to the pro‐hormone convertases and disintegrin families. The delineation of respective contributions of proteolytic activities in constitutive and regulated sAPPα secretion is rendered difficult by the fact that the overall regulated response always includes the basal constitutive counterpart that cannot be selectively abolished. Here we report on the fact that the furin‐deficient LoVo cells are devoid of regulated PKC‐dependent sAPPα secretion and therefore represent an interesting model to study exclusively the constitutive sAPPα secretion. We show here, by a pharmacological approach using selective inhibitors, that pro‐hormone convertases and proteases of the ADAM (disintegrin metalloproteases) family participate in the production/secretion of sAPPαs in LoVo cells. Transfection analysis allowed us to further establish that the pro‐hormone convertase 7 and ADAM10 but not ADAM17 (TACE, tumour necrosis factor α‐converting enzyme) likely contribute to constitutive sAPPα secretion by LoVo cells.
Journal of Cell Science | 2005
Silvia Jansen; Cristiana Stefan; John Creemers; Etienne Waelkens; Aleyde Van Eynde; Willy Stalmans; Mathieu Bollen
Autotaxin (NPP2) is an extracellular protein that is upregulated in various malignancies, including breast and lung cancer. It potently stimulates cell proliferation, cell motility and angiogenesis, which is accounted for by its intrinsic lysophospholipase-D activity that generates the lipid mediators lysophosphatidic acid and sphingosine-1-phosphate. Based on its structural similarities with the better characterized nucleotide pyrophosphatase/phosphodiesterase NPP1, it has always been assumed that NPP2 is also synthesized as a type-II integral membrane protein and that extracellular NPP2 is generated from this membrane precursor. We show here, however, using domain swapping and mutagenesis experiments as well as N-terminal protein sequencing, that NPP2 is actually synthesized as a pre-pro-enzyme and that the proteolytically processed protein is secreted. Following the removal of a 27-residue signal peptide by the signal peptidase, NPP2 is subsequently cleaved by proprotein convertases (PCs). The removal of an N-terminal octapeptide by PCs is associated with an enhanced activity of NPP2 as a lysophospholipase D. These novel insights in the maturation of NPP2 have also implications for the development of NPP2 inhibitors as potential anti-cancer agents.
Journal of Biological Chemistry | 2011
Rachid Essalmani; Delia Susan-Resiga; Ann Chamberland; Marianne Abifadel; John Creemers; Catherine Boileau; Nabil G. Seidah; Annik Prat
The proprotein convertase PCSK9 plays a key role in cholesterol homeostasis by binding the LDL receptor and targeting it toward degradation. PCSK9 is strongly expressed in the liver and is found in human and mouse plasma as mature (∼62 kDa) and inactivated (∼55 kDa) forms. Ex vivo data showed that human PCSK9 is inactivated by cleavage at Arg218↓ by the overexpressed convertases furin and PC5/6A. Analysis of the plasma of human heterozygotes for R218S and F216L mutations revealed a ∼50% reduction in the levels of the ∼55-kDa form. To identify the convertase(s) responsible for cleavage at Arg218 in vivo, we inactivated the genes of furin and/or PC5/6 specifically in hepatocytes. The PCSK9-inactivated form was strongly reduced in mice lacking furin in hepatocytes (Fur-hKO) and only slightly reduced in PC5/6-hKO plasma. In agreement with a key role of furin in regulating PCSK9 activity in vivo, we observed an overall 26% drop in the LDL receptor protein levels of Fur-hKO livers, likely due to the compound effects of a 35% increase in PCSK9 mRNA levels and the loss of PCSK9 cleavage, suggesting a higher activity of PCSK9 in these mice. Overexpression of PCSK9 in primary hepatocytes obtained from these mice revealed that only full-length, membrane-bound, but not soluble, furin is the cognate convertase. We conclude that in hepatocytes furin regulates PCSK9 mRNA levels and is the key in vivo-inactivating protease of circulating PCSK9.
Journal of Biological Chemistry | 2004
Anton Roebroek; Neil A. Taylor; Els Louagie; Ilse Pauli; Liesbeth Smeijers; An Snellinx; A. Lauwers; Wim J.M. Van de Ven; Dieter Hartmann; John Creemers
Furin is an endoprotease of the family of mammalian proprotein convertases and is involved in the activation of a large variety of regulatory proteins by cleavage at basic motifs. A large number of substrates have been attributed to furin on the basis of in vitro and ex vivo data. However, no physiological substrates have been confirmed directly in a mammalian model system, and early embryonic lethality of a furin knock-out mouse model has precluded in vivo verification of most candidate substrates. Here, we report the generation and characterization of an interferon inducible Mx-Cre/loxP furin knock-out mouse model. Induction resulted in near-complete ablation of the floxed fur exon in liver. In sharp contrast with the general furin knock-out mouse model, no obvious adverse effects were observed in the transgenic mice after induction. Histological analysis of the liver did not reveal any overt deviations from normal morphology. Analysis of candidate substrates in liver revealed complete redundancy for the processing of the insulin receptor. Variable degrees of redundancy were observed for the processing of albumin, α5 integrin, lipoprotein receptor-related protein, vitronectin and α1-microglobulin/bikunin. None of the tested substrates displayed a complete block of processing. The absence of a severe phenotype raises the possibility of using furin as a local therapeutic target in the treatment of pathologies like cancer and viral infections, although the observed redundancy may require combination therapy or the development of a more broad spectrum convertase inhibitor.
Cell Metabolism | 2014
Bas Brouwers; Geoffroy de Faudeur; Anna B. Osipovich; Lotte Goyvaerts; Katleen Lemaire; Leen Boesmans; Elisa J.G. Cauwelier; Mikaela Granvik; Vincent P. E. G. Pruniau; Leentje Van Lommel; Jolien Van Schoors; Jennifer S. Stancill; Ilse Smolders; Vincent Goffin; Nadine Binart; Peter In’t Veld; Jeroen Declercq; Mark A. Magnuson; John Creemers; Frans Schuit; Anica Schraenen
The human growth hormone (hGH) minigene is frequently used in the derivation of transgenic mouse lines to enhance transgene expression. Although this minigene is present in the transgenes as a secondcistron, and thus not thought to be expressed, we found that three commonly used lines, Pdx1-Cre(Late), RIP-Cre, and MIP-GFP, each expressed significant amounts of hGH in pancreatic islets. Locally secreted hGH binds to prolactin receptors on β cells, activates STAT5 signaling, and induces pregnancy-like changes in gene expression, thereby augmenting pancreatic β cell mass and insulin content. In addition, islets of Pdx1-Cre(Late) mice have lower GLUT2 expression and reduced glucose-induced insulin release and are protected against the β cell toxin streptozotocin. These findings may be important when interpreting results obtained when these and other hGH minigene-containing transgenic mice are used.